Table 2 Influence of pioglitazone on glycaemic and lipid profile, weight and BMI in patients with T2DM
From: Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis
| Author, year | FPG* (mmol/l) | HbA1c* (%) | Total cholesterol* (mmol/l) | LDL* (mmol/l) | HDL* (mmol/l) | Triglycerides* (mmol/l) | BMI* (kg/m2) | Weight* (kg) |
|---|---|---|---|---|---|---|---|---|
| Berhanu et al. [13] | 0.47 (− 0.14; 1.09) | − 1.60 (− 1.82; − 1.38) | 0.15 (0.01; 0.27) | 0.10 (− 0.02; 0.22) | 0.11 (0.07; 0.15) | − 0.002 (− 0.22; 0.22) | ||
| Belfort et al. [14] | − 1.11 (− 1.93; − 0.29) | − 0.70 (− 1.35; − 0.05) | 0.13 (− 0.36; 0.61) | 0.05 (− 0.41; 0.52) | 0.08 (− 0.05; 0.20) | − 0.27 (− 0.80; 0.25) | 1.1 (− 1.79; 3.99) | 2.5 (− 7.97; 12.97) |
| DeFronzo et al. [16] | − 0.59 (− 0.67; − 0.50) | 0.50 (0.49; 0.51) | − 1.1 (− 1.17; − 1.03) | 1.4 (1.32; 1.48) | 3.8 (3.60; 4.00) | |||
| DeFronzo et al. [17] | − 0.22 (− 0.23; − 0.21) | 1.6 (1.21; 1.99) | ||||||
| Mattoo et al. [15] | − 1.22 (− 2.24; − 0.20) | − 0.74 (− 1.01; − 0.47) | − 0.2 (− 0.24; 0.20) | 0.12 (0.04; 0.19) | ||||
| Rosenstock et al. (15 mg) [18] | − 1.91 (− 2.46; − 1.37) | − 0.99 (− 1.15; − 0.83) | 0.13 (0.04; 0.22) | 0.18 (0.10; 0.26) | 0.06 (− 0.09; 0.21) | |||
| Rosenstock et al. (30 mg) [18] | − 2.67 (− 3.22; − 2.12) | − 1.26 (− 1.42; − 1.10) | 0.07 (− 0.02; 0.02) | 0.24 (0.16; 0.32) | − 0.12 (− 0.26; 0.03) | |||
| Davidson et al. (30 mg) [19] | − 1.77 (− 2.21; − 1.33) | − 1.20 (− 1.36; − 1.04) | 0.17 (0.08; 0.25) | 0.25 (0.19; 0.31) | − 0.05 (− 0.12; 0.01) | |||
| Davidson et al. (45 mg) [19] | − 2.54 (− 2.98; − 2.11) | − 1.50 (− 1.66; − 1.34) | 0.17 (0.08; 0.26) | 0.34 (0.27; 0.40) | − 0.07 (− 0.13; − 0.002) | |||
| Goldberg et al. [3] | − 1.84 (− 2.08; − 1.60) | − 0.70 (− 0.90; − 0.50) | 0.23 (0.13; 0.32) | 0.32 (0.24; 0.40) | 0.13 (0.11; 0.16) | − 0.59 (− 0.76; − 0.41) | 2.0 (1.64; 2.39) | |
| Panikar et al. (7.5 mg) [22] | − 1.24 (− 2.51; 0.03) | 0.88 (− 4.55; 6.31) | 0.33 (− 1.65; 2.31) | |||||
| Panikar et al. (15 mg) [22] | − 1.18 (− 2.34; − 0.02) | 1.62 (− 4.08; 7.32) | 0.62 (− 1.54; 2.78) | |||||
| Panikar et al. (30 mg) [22] | − 1.25 (− 2.90; 0.40) | 2.72 (− 3.10; 8.54) | 1.03 (− 1.20; 3.26) | |||||
| Xu et al. [20] | − 2.00 (− 2.39; − 1.61) | − 1.50 (− 1.70; − 1.30) | − 0.10 (− 0.30; 0.10) | − 0.10 (− 0.30; 0.10) | 0.16 (0.12; 0.20) | − 0.20 (− 0.40; − 0.004) | 0.00 (− 0.20; 0.20) | 0.00 (− 0.78; 0.78) |
| Yoshii et al. [25] | − 0.22 (− 0.33; − 0.08) | 0.12 (0.05; 0.19) | ||||||
| Bolli et al. [12] | − 1.60 (− 1.95; − 1.33) | − 0.60 (− 0.71; − 0.45) | 2.60 (2.01; 3.19) | |||||
| Kodama et al. [23] | − 0.36 (− 0.73; 0.01) | − 0.01 (− 0.34; 0.32) | 0.14 (− 0.03; 0.31) | 0.60 (− 5.45; 6.65) | ||||
| Shah et al. [24] | − 0.5 (− 0.77; − 0.23) | 1.5 (1.11; 1.89) | 4.9 (− 3.92; 13.72) | |||||
| Gerber et al. (30 mg) [21] | − 2.6 (− 1.39; − 0.90) | − 1.1 (− 3.26; 1.06) | − 0.13 (− 1.87; 1.61) | − 0.01 (− 1.56; 1.54) | 0.11 (− 0.68; 0.68) | − 0.87 (− 3.03; 4.77) | 2.6 (− 2.89; 8.09) | |
| Gerber et al. (30/45 mg) [21] | − 1.9 (− 1.38; − 0.73) | − 1.1 (− 3.84; 1.64) | − 0.03 (− 2.62; 2.56) | − 0.12 (− 1.69; 1.45) | 0.12 (− 0.55; 0.79) | − 0.60 (− 4.56; 5.16) | 2.7 (− 3.18; 8.58) | |
| Gerber et al. (45 mg) [21] | − 1.5 (− 1.23; − 0.52) | − 0.9 (− 4.04; 2.24) | − 0.12 (− 1.61; 1.37) | 0.08 (− 0.37; 0.53) | − 0.28 (− 3.28; 2.72) | 2.8 (− 3.67; 9.27) |